Phase I study of bortezomib in refractory of relapsed acute leukemias

Jorge Cortes, Deborah Thomas, Charles Koller, Francis Giles, Elihu Estey, Stefan Faderl, Guillermo Garcia-Manero, David McConkey, Gira Patel, Roberto Guerciolini, John Wright, Hagop Kantarjian

Research output: Contribution to journalArticle

Abstract

Bortezomib (Velcade, formerly PS-341) is proteasome inhibitor with documented antitumor activity in multiple myeloma and other lymphoid malignancies. We performed a Phase I study to investigate the maximum tolerated dose and dose-limiting toxicity of bortezomib in patients with acute leukemias refractory to or relapsing after prior therapy. Fifteen patients were treated with 0.75 (n = 3), 1.25 (n = 7), or 1.5 (n = 5) mg/m2 bortezomib administered twice weekly for 4 weeks every 6 weeks. Dose-limiting toxicity included orthostatic hypotension (n = 2), nausea (n = 2), diarrhea (n = 1), and fluid retention (n = 1), all at 1.5 mg/m2 bortezomib. Proteasome inhibition was dose dependent and reached 68% at 1.5 mg/m2 bortezomib. Peak inhibition was observed 1 h after treatment and returned to near baseline levels by 72 h after treatment. Incubation of blast cells with bortezomib in vitro showed induction of apoptosis in three of five patients investigated. We conclude that the maximum tolerated dose of bortezomib in patients with acute leukemia is 1.25 mg/m2, using a twice-weekly for 4 weeks every 6 weeks schedule. The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents.

Original languageEnglish (US)
Pages (from-to)3371-3376
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number10
DOIs
StatePublished - May 15 2004
Externally publishedYes

Fingerprint

Leukemia
Maximum Tolerated Dose
Bortezomib
Orthostatic Hypotension
Proteasome Inhibitors
Proteasome Endopeptidase Complex
Multiple Myeloma
Nausea
Diarrhea
Appointments and Schedules
Therapeutics
Apoptosis
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cortes, J., Thomas, D., Koller, C., Giles, F., Estey, E., Faderl, S., ... Kantarjian, H. (2004). Phase I study of bortezomib in refractory of relapsed acute leukemias. Clinical Cancer Research, 10(10), 3371-3376. https://doi.org/10.1158/1078-0432.CCR-03-0508

Phase I study of bortezomib in refractory of relapsed acute leukemias. / Cortes, Jorge; Thomas, Deborah; Koller, Charles; Giles, Francis; Estey, Elihu; Faderl, Stefan; Garcia-Manero, Guillermo; McConkey, David; Patel, Gira; Guerciolini, Roberto; Wright, John; Kantarjian, Hagop.

In: Clinical Cancer Research, Vol. 10, No. 10, 15.05.2004, p. 3371-3376.

Research output: Contribution to journalArticle

Cortes, J, Thomas, D, Koller, C, Giles, F, Estey, E, Faderl, S, Garcia-Manero, G, McConkey, D, Patel, G, Guerciolini, R, Wright, J & Kantarjian, H 2004, 'Phase I study of bortezomib in refractory of relapsed acute leukemias', Clinical Cancer Research, vol. 10, no. 10, pp. 3371-3376. https://doi.org/10.1158/1078-0432.CCR-03-0508
Cortes, Jorge ; Thomas, Deborah ; Koller, Charles ; Giles, Francis ; Estey, Elihu ; Faderl, Stefan ; Garcia-Manero, Guillermo ; McConkey, David ; Patel, Gira ; Guerciolini, Roberto ; Wright, John ; Kantarjian, Hagop. / Phase I study of bortezomib in refractory of relapsed acute leukemias. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 10. pp. 3371-3376.
@article{329102249bee414b9ec7be18af6e53d9,
title = "Phase I study of bortezomib in refractory of relapsed acute leukemias",
abstract = "Bortezomib (Velcade, formerly PS-341) is proteasome inhibitor with documented antitumor activity in multiple myeloma and other lymphoid malignancies. We performed a Phase I study to investigate the maximum tolerated dose and dose-limiting toxicity of bortezomib in patients with acute leukemias refractory to or relapsing after prior therapy. Fifteen patients were treated with 0.75 (n = 3), 1.25 (n = 7), or 1.5 (n = 5) mg/m2 bortezomib administered twice weekly for 4 weeks every 6 weeks. Dose-limiting toxicity included orthostatic hypotension (n = 2), nausea (n = 2), diarrhea (n = 1), and fluid retention (n = 1), all at 1.5 mg/m2 bortezomib. Proteasome inhibition was dose dependent and reached 68{\%} at 1.5 mg/m2 bortezomib. Peak inhibition was observed 1 h after treatment and returned to near baseline levels by 72 h after treatment. Incubation of blast cells with bortezomib in vitro showed induction of apoptosis in three of five patients investigated. We conclude that the maximum tolerated dose of bortezomib in patients with acute leukemia is 1.25 mg/m2, using a twice-weekly for 4 weeks every 6 weeks schedule. The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents.",
author = "Jorge Cortes and Deborah Thomas and Charles Koller and Francis Giles and Elihu Estey and Stefan Faderl and Guillermo Garcia-Manero and David McConkey and Gira Patel and Roberto Guerciolini and John Wright and Hagop Kantarjian",
year = "2004",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-03-0508",
language = "English (US)",
volume = "10",
pages = "3371--3376",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Phase I study of bortezomib in refractory of relapsed acute leukemias

AU - Cortes, Jorge

AU - Thomas, Deborah

AU - Koller, Charles

AU - Giles, Francis

AU - Estey, Elihu

AU - Faderl, Stefan

AU - Garcia-Manero, Guillermo

AU - McConkey, David

AU - Patel, Gira

AU - Guerciolini, Roberto

AU - Wright, John

AU - Kantarjian, Hagop

PY - 2004/5/15

Y1 - 2004/5/15

N2 - Bortezomib (Velcade, formerly PS-341) is proteasome inhibitor with documented antitumor activity in multiple myeloma and other lymphoid malignancies. We performed a Phase I study to investigate the maximum tolerated dose and dose-limiting toxicity of bortezomib in patients with acute leukemias refractory to or relapsing after prior therapy. Fifteen patients were treated with 0.75 (n = 3), 1.25 (n = 7), or 1.5 (n = 5) mg/m2 bortezomib administered twice weekly for 4 weeks every 6 weeks. Dose-limiting toxicity included orthostatic hypotension (n = 2), nausea (n = 2), diarrhea (n = 1), and fluid retention (n = 1), all at 1.5 mg/m2 bortezomib. Proteasome inhibition was dose dependent and reached 68% at 1.5 mg/m2 bortezomib. Peak inhibition was observed 1 h after treatment and returned to near baseline levels by 72 h after treatment. Incubation of blast cells with bortezomib in vitro showed induction of apoptosis in three of five patients investigated. We conclude that the maximum tolerated dose of bortezomib in patients with acute leukemia is 1.25 mg/m2, using a twice-weekly for 4 weeks every 6 weeks schedule. The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents.

AB - Bortezomib (Velcade, formerly PS-341) is proteasome inhibitor with documented antitumor activity in multiple myeloma and other lymphoid malignancies. We performed a Phase I study to investigate the maximum tolerated dose and dose-limiting toxicity of bortezomib in patients with acute leukemias refractory to or relapsing after prior therapy. Fifteen patients were treated with 0.75 (n = 3), 1.25 (n = 7), or 1.5 (n = 5) mg/m2 bortezomib administered twice weekly for 4 weeks every 6 weeks. Dose-limiting toxicity included orthostatic hypotension (n = 2), nausea (n = 2), diarrhea (n = 1), and fluid retention (n = 1), all at 1.5 mg/m2 bortezomib. Proteasome inhibition was dose dependent and reached 68% at 1.5 mg/m2 bortezomib. Peak inhibition was observed 1 h after treatment and returned to near baseline levels by 72 h after treatment. Incubation of blast cells with bortezomib in vitro showed induction of apoptosis in three of five patients investigated. We conclude that the maximum tolerated dose of bortezomib in patients with acute leukemia is 1.25 mg/m2, using a twice-weekly for 4 weeks every 6 weeks schedule. The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents.

UR - http://www.scopus.com/inward/record.url?scp=2542481724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542481724&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-03-0508

DO - 10.1158/1078-0432.CCR-03-0508

M3 - Article

C2 - 15161691

AN - SCOPUS:2542481724

VL - 10

SP - 3371

EP - 3376

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -